港股主要指数上涨，亚盛医药涨超6%，信达生物、三生制药、联邦制药、再鼎医药涨超3%，带动港股创新药精选ETF（520690）今日上涨1.8%，冲击四连涨，近4日上涨8.8%，净值创上市新高。 自8月1日上市以来，港股创新药精选ETF（520690）资金净流入额6268万元，其最新规模4.03亿元。 港股创新药精选ETF跟踪恒生港股通创新药精选指数，聚焦港股创新药龙头与高研发属性标的，适合进攻性获取创新药板块β。 今年以来，港股创新药强势上涨，港股创新药精选ETF标的指数年内涨幅111%。 业内人士认为，政策对于创新药行业的支持已形成了一套全面且系统的体系，贯穿了从研发到商业化、从本土市场培育到国际市场拓展的全链条，为港股创新药企业的茁壮成长提供了坚实有力的保障。另外，凭借创新主体、服务支撑、资本枢纽三位一体的协同架构，港股创新药行业形成独特的生态护城河，尤其是港股“18A”通道突破了传统A股盈利指标的限制，打通从研发阶段融资到上市后价值释放的链条 国金证券指出，在全球医药产业持续革新的浪潮中，创新药板块正逐步引起市场的高度关注，港股创新药行业的核心投资价值源于估值历史低位与基本面加速改善的错配，形成较高性价比的配置窗口。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.